Bausch + Lomb to acquire Xiidra, ‘front of eye’ assets from Novartis

Bausch + Lomb to acquire Xiidra, ‘front of eye’ assets from Novartis

Source: 
Healio
snippet: 
  • Bausch + Lomb will acquire Xiidra and other assets from Novartis for a transaction of up to $2.5 billion.
  • The deal is expected to close later this year.